You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 301 No. 4, January 28, 2009 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Research Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Topic Collections
 •Aging/ Geriatrics
 •Viral Infections
 •Cardiovascular System
 •Cardiovascular Disease/ Myocardial Infarction
 •Infectious Diseases
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Cytomegalovirus Antibody Level and Mortality Among Community-Dwelling Older Adults With Stable Cardiovascular Disease

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: Clinically meaningful cytomegalovirus (CMV) infection is not limited to immunocompromised hosts,1 as recently demonstrated in critically ill immunocompetent patients.2 Cytomegalovirus may have an increasing effect in an aging society. Cross-sectional analyses have shown its association with frailty and functional impairment3-4 and, along with seropositivity to other herpesviruses, an association with impaired cognition among community-dwelling older individuals.5 We therefore prospectively studied the association between CMV IgG levels and mortality.

Methods

These analyses are secondary analyses of the Drugs and Evidence-Based Medicine in the Elderly (DEBATE) trial. The 400 participants were recruited from 4821 randomly selected community-living individuals in Helsinki, Finland, during 1999 and 2000.6 The DEBATE trial was approved by the ethics committee and participants provided written consent. The mean age was 80 years (range, 75-90 years; 65% women) (Table 1), and all participants had a history of cardiovascular disease that was stable at baseline.


 
Table appears in full text version.
Table 1. . . . [Full Text of this Article]


Timo E. Strandberg, MD, PhD
timo.strandberg@oulu.fi
Unit of General Practice
University Hospital of Oulu
Oulu, Finland

Kaisu H. Pitkala, MD, PhD
Unit of General Practice

Reijo S. Tilvis, MD, PhD
Clinic of Internal Medicine and Geriatrics
University Central Hospital of Helsinki
Helsinki, Finland



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.